Jorge J. Nieva, MD

Articles by Jorge J. Nieva, MD

Addressing Learning Curves in Rare NSCLC Subtypes and Targeted Therapy Use: Jorge Nieva, MD

ByJorge J. Nieva, MD,Alana Hippensteele, MA

September 1st 2025

Jorge Nieva, MD, explores the challenges of translating biomarker testing into treatment decisions for non–small cell lung cancer (NSCLC), the role of repeat testing in detecting resistance mutations, and the importance of equitable access to molecular diagnostics in value-based care settings.

Overcoming Barriers to Molecular Testing in NSCLC Care: Jorge Nieva, MD

ByJorge J. Nieva, MD,Alana Hippensteele, MA

August 29th 2025

Jorge Nieva, MD, highlights the critical role of molecular testing in non–small cell lung cancer (NSCLC) care, while addressing barriers such as limited tissue samples, delayed turnaround times, and the need for faster, more accessible diagnostic technologies.

Jorge J. Nieva, MD, Keck School of Medicine

Breaking Down Taletrectinib’s FDA Approval: Jorge J. Nieva, MD

ByMaggie L. Shaw,Jorge J. Nieva, MD

June 20th 2025

In this interview with TRUST-I and TRUST-II trial investigator, Jorge J. Nieva, MD, USC Keck School of Medicine, he walks through the design of the trials, the results that supported the FDA approval, and taletrectinib’s potential to redefine first-line therapy.